Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX
申请人:Molecular Insight Pharmaceuticals, Inc.
公开号:US09422251B2
公开(公告)日:2016-08-23
A ligand, a pharmaceutically acceptable salt, tautomer, or ester thereof, may be represented as:
In the formula, X is selected from the group consisting of —(CH2)n—, —(CH2)n—O—, —(CH2)n—N(Rg)—, —(CH2)n—N(Rg)—C(O)— and —O—; Rg is hydrogen or (C1-C6)alkyl; G is —(CH(Rm))n—Rh—, or —(CH2)p—C(O)—Rh; G′ is —(CH(Rm))n—Rh—, or —(CH2)p—C(O)—Rh; Rh is —H, —OH, NRaRb, or —CO2H; Rm is —H, —COOH, or substituted or unsubstituted —COO(C1-C6)alkyl; Ra and Rb are each independently H, substituted or unsubstituted (C1-C8)alkyl, or substituted or unsubstituted carboxy(C1-C8)alkylene; m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and p is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
一种
配体,一种药学上可接受的盐,互变异构体或酯可以表示为:在公式中,X是从群组中选择的,该群组包括—(
CH2)n—,—( )n—O—,—( )n—N(Rg)—,—( )n—N(Rg)—C(O)—和—O—;Rg是氢或(C1-C6)烷基;G是—(CH(Rm))n—Rh—,或—( )p—C(O)—Rh;G'是—(CH(Rm))n—Rh—,或—( )p—C(O)—Rh;Rh是—H,—OH,NRaRb或—CO2H;Rm是—H,—COOH或取代或未取代的—COO(C1-C6)烷基;Ra和Rb各自独立地为H,取代或未取代的(C1-C8)烷基,或取代或未取代的羧基(C1-C8)烷基;m为0、1、2、3、4、5、6、7、8、9或10;n为0、1、2、3、4、5、6、7、8、9或10;p为0、1、2、3、4、5、6、7、8、9或10。